For the quarter ending 2026-03-31, UNCY had $8,173K increase in cash & cash equivalents over the period. -$6,249K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | -12,823 | -14,668 | -6,010 | -5,877 |
| Depreciation expense | 8 | 10 | 10 | 14 |
| Loss on disposal of assets | -18 | - | - | - |
| Stock-based compensation expense | 754 | 777 | 730 | 1,134 |
| Change in fair value of warrant liability | 4,780 | 7,768 | -1,067 | -8,722 |
| Amortization of operating lease right of use asset | 203 | 141 | 138 | 259 |
| Amortization of investments in marketable securities | 12 | - | - | - |
| Prepaid expense and other current assets | 1,267 | 98 | 394 | 2,392 |
| Accounts payable and accrued liabilities | 2,285 | -1,814 | 775 | -1,466 |
| Operating lease liability | -211 | -148 | -144 | -273 |
| Net cash used in operating activities | -6,241 | -8,032 | -5,962 | -17,323 |
| Purchases of marketable securities | 5,149 | 12,071 | - | - |
| Purchases of property and equipment | 8 | 0 | 2 | 22 |
| Realized gain on marketable securities | -2 | - | - | - |
| Issuance costs related to issuance of series b-1 preferred stock | - | - | - | 0 |
| Net cash used in investing activities | -5,155 | -12,071 | -2 | -22 |
| Payments on financed insurance policies | - | 0 | 1 | 211 |
| Proceeds from exercise of warrants | - | 0 | 0 | 1,496 |
| Proceeds from issuance of series b-1 preferred stock | - | - | - | 0 |
| Dividends on preferred stock | - | - | - | 0 |
| Gross proceeds from secondary public offering | 20,174 | 6,811 | 27,147 | 12,624 |
| Commissions paid on secondary public offering | 605 | 205 | 814 | 379 |
| Net cash provided by financing activities | 19,569 | 6,606 | 26,332 | 13,530 |
| Net increase (decrease) in cash and cash equivalents | 8,173 | -13,497 | 20,368 | -3,815 |
| Cash and cash equivalents at the beginning of the period | 29,198 | 42,695 | 26,142 | - |
| Cash and cash equivalents at the end of the period | 37,371 | 29,198 | 42,695 | - |
Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. (UNCY)